Takeda Offers $106.3M to Back Heptares' Schizophrenia Leads
By Nuala Moran
Tuesday, April 12, 2011
LONDON Heptares Therapeutics Ltd. signed a deal worth a potential £65 million (US$106.3 million) with Takeda Pharmaceutical Co., to characterize the structure and deliver early leads against a G-protein coupled receptor (GPCR) that is involved in schizophrenia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.